Brief: Ryvu Therapeutics Performed Dosing Of First Patient In Remark Phase II Study Of RVU120

Ryvu Therapeutics SA

19/09/2024 06:53

Sept 19 (Reuters) - Ryvu Therapeutics SA  RVU.WA :
    * PERFORMED DOSING OF FIRST PATIENT IN REMARK PHASE II STUDY
OF
RVU120
    * TRIAL ON TREATMENT OF ANEMIA IN PATIENTS WITH LOWER-RISK
MYELODYSPLASTIC SYNDROMES

Source text for Workspace:  urn:newsml:reuters.com:*:nEMPmYFSa
Further company coverage:  RVU.WA 

 (Reporting by Gdańsk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))